Injectable Formulations From the single-target GLP-1 drug Semaglutide, to the dual-target GLP-1/GIP Tirzepatide, and then to the triple-target GLP-1/GIP/GCG Retatrutide, the weight loss curves over time for these three have essentially divided the entire field into several distinct tiers: Any pipeline falling below the Semaglutide curve is basically out of the running
Retatrutide is not started at the maintenance dose
When scaling protocols from rodent data to higher-order models, researchers should apply allometric correction factors rather than relying on raw values from a peptide half-life chart calibrated to one species
This means that people taking Ozempic may develop blood clots as a result of taking the drug
In May 2024, Nestl launched Vital Pursuit, a range of foods designed to complement GLP-1 weight loss medications
How does the glucagon receptor component change the drug interaction profile